Replimune Group (NASDAQ:REPL) Stock Price Down 14.8% – Should You Sell?

Shares of Replimune Group, Inc. (NASDAQ:REPL) fell 14.8% during trading on Monday . The stock traded as low as $8.26 and last traded at $8.2920. 1,702,178 shares changed hands during trading, a decline of 62% from the average session volume of 4,482,394 shares. The stock had previously closed at $9.73.

Analysts Set New Price Targets

Several brokerages recently commented on REPL. Leerink Partnrs raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Cantor Fitzgerald upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 30th. Jefferies Financial Group reduced their price objective on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $3.00 to $13.00 in a research note on Monday, October 20th. Finally, BMO Capital Markets downgraded shares of Replimune Group from an “outperform” rating to an “underperform” rating and reduced their price target for the stock from $27.00 to $2.00 in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.75.

Replimune Group Stock Performance

The stock has a market capitalization of $725.53 million, a P/E ratio of -2.87 and a beta of 0.42. The company’s 50-day moving average is $5.81 and its two-hundred day moving average is $7.40. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In related news, CFO Emily Luisa Hill sold 9,154 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the sale, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.20% of the stock is owned by insiders.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its holdings in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares in the last quarter. Deutsche Bank AG increased its position in shares of Replimune Group by 0.4% in the first quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock worth $5,496,000 after acquiring an additional 2,140 shares in the last quarter. Arizona State Retirement System increased its position in shares of Replimune Group by 19.7% in the first quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock worth $151,000 after acquiring an additional 2,545 shares in the last quarter. MetLife Investment Management LLC increased its position in shares of Replimune Group by 7.8% in the first quarter. MetLife Investment Management LLC now owns 40,598 shares of the company’s stock worth $396,000 after acquiring an additional 2,939 shares in the last quarter. Finally, Corebridge Financial Inc. increased its position in shares of Replimune Group by 11.0% in the first quarter. Corebridge Financial Inc. now owns 33,584 shares of the company’s stock worth $327,000 after acquiring an additional 3,317 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.